Skip to main content
OpenTrials
Completed

NCT Number: NCT01612689

3-Dimensional Accelerometer Sub-Study

This is a prospective, unblinded sub-study to the E-30 to gather physiological data.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gainesville, Florida, United States

Loading trial locations.

About this study

This sub-study to the E-30 is designed to collect vital signs, accelerometer and ECG data on subjects, and will consist of two phases. Phase 1 is designed to collect data in an Epilepsy Monitoring Unit (EMU) and Phase 2 is designed to collect data in an everyday (ambulatory) setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Phase 1)

  • Subject be scheduled to participated in the E-30 parent study for a minimum of 48 hours
  • Subject has a clinical diagnosis of epilepsy based on a prior EMU visit

(Phase 1&2)

  • Subject is currently enrolled or previously participated in the E-30 study
  • Subject must be 6 years of age or older

(Sleep State: Optional)

  • Subject must be 12 years of age
  • Subject is currently enrolled in the E-30S sub-study and is willing to stay in a light controlled environment in the EMU for up to 120 hours

Exclusion criteria

(Phase 1&2)

  • Subjects with a medical condition that in the opinion of the investigator would affect his/her ability to participate in the sub-study.
  • Subject who has implanted defibrillator, pacemaker or Vagus Nerve Stimulation Therapy® (VNS) System
  • Subjects who are pregnant or lactating
  • Subjects with severe psychiatric disease that in the opinion of the investigator would prevent the subject's successful completion of the sub-study.
  • Subjects 6 to 16 years of age with moderate/severe learning difficulties or those who may be at risk of self-harm.
  • Subjects prescribed drugs specifically for a cardiac or autonomic disorder that in the investigator's opinion would affect heart rate response unless the patient has ictal tachycardia while taking said drugs. These include, but are not limited to, beta adrenergic antagonists ("beta blockers").
  • Subjects with cardiovascular arrhythmias or cardiac disease that would preclude the ability to detect intrinsic changes in heart rate due to activity, stress, or seizure. This would include but not be limited to chronic atrial fibrillation or chronotropic incompetence.
  • Subjects with a history of dependence on alcohol or narcotic drugs within the past 2 years as defined by DSM IV-R.

(Sleep State: Optional)

  • Subjects with a history if gastrointestinal disease (GI)or GI surgery
  • Subjects with a history of difficulty swallowing
  • Subjects with diabetes mellitus
  • Subjects with uncontrolled hypertension
  • Subjects with planned MRI during EMU stay

Treatment and study plan

Accelerometer Device

Device

A sensor platform that enables physiological monitoring in routine, home or office environments.

Primary outcomes

  1. Gather physiological data

    Time frame: Up to 2 weeks

    The purpose of this sub-study is to gather physiological data in consenting subjects who were previously enrolled in the "parent" E-30 study (NCT01202669).

Sponsors and collaborators

Lead sponsor

Cyberonics, Inc.

Industry

Registry information

Official study title

3-Dimensional Accelerometer Sub-Study for Patients Participating in the E-30 Study: Heart Rate Changes in Subjects With Epilepsy During an Epilepsy Monitoring Unit Admission

Important dates

Study start
2012
Primary completion
2012
Study completion
2014
First posted
Jun 6, 2012
Registry last updated
Aug 7, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.